For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

TB-500 and thymosin beta-4: origin, structure and research history

Research Library › Peptide Fragments

TB-500 is a synthetic, acetylated seven-amino-acid peptide (LKKTETQ) that reproduces the actin-binding segment of thymosin beta-4, a naturally occurring 43-amino-acid protein first isolated from calf thymus. Thymosin beta-4 was characterized in Allan L. Goldstein’s laboratory, which published its full sequence in 1981, and the short fragment traces to a 2003 study. As of 22 Oct 2026 neither TB-500 nor thymosin beta-4 is FDA-approved.

Key facts

TypeSynthetic 7-amino-acid peptide with an acetyl cap
SequenceAc-LKKTETQ (Leu-Lys-Lys-Thr-Glu-Thr-Gln)
Derived fromThymosin beta-4, a natural 43-amino-acid protein first isolated from calf thymus
First describedThymosin beta-4 sequenced 1981; actin-binding fragment studied 2003
Developed byAllan L. Goldstein (George Washington University; founder of RegeneRx), with Hynda Kleinman's group for the 2003 fragment work
Designed targetActin, the cytoskeletal protein involved in cell movement
Regulatory status (Oct 2026)Not FDA-approved; PCAC voted 8–6–1 on TB-500 compounding in July 2026; no final FDA decision

Who developed it

Thymosin beta-4 was discovered by Allan L. Goldstein, former chair of biochemistry at George Washington University. In 1982 he founded the company now known as RegeneRx Biopharmaceuticals [1, 2]. His laboratory published the protein’s complete amino acid sequence in 1981 [3].

TB-500 traces back to a 2003 paper co-authored by Goldstein and Hynda Kleinman’s group. That study compared the full protein with a synthetic peptide containing only its actin-binding domain [4, 5].

What it was designed to target

Thymosin beta-4 is a natural 43-amino-acid protein first extracted from calf thymus [3]. Biochemists later showed it is identical to Fx, a peptide that binds and sequesters actin, the protein that forms the internal scaffolding cells use to change shape and move [6].

TB-500 is a lab-made copy of just seven of those 43 amino acids, LKKTETQ, with an acetyl group capping one end. It was designed to represent the actin-binding region of the parent protein. The FDA’s 2026 briefing document states plainly that TB-500 and thymosin beta-4 are not the same substance [5].

Why it was created

Thymosin beta-4 was first described as a thymic hormone associated with the maturation of immune cells [3]. Research interest later shifted toward tissue repair: by 2001 RegeneRx had licensed rights from the US National Institutes of Health to develop the protein as a tissue repair factor [2].

RegeneRx’s lead program, RGN-259, is an eye-drop formulation of the full-length protein originally investigated in a research program on corneal conditions [2]. A larger corneal trial, SEER-2, has finished, with topline results targeted for mid-November 2026 [7]. The FDA’s 2026 review found no published articles in which TB-500 itself was given to people; all human studies used the full protein [2, 5].

Research timeline

  • 1981: Full amino acid sequence of thymosin beta-4 published [3]
  • 1982: Goldstein founds the company now called RegeneRx [1]
  • 1991: Thymosin beta-4 shown to be identical to the actin-sequestering peptide Fx [6]
  • 2001: RegeneRx licenses NIH rights for tissue repair research [2]
  • 2003: Synthetic actin-binding fragment studied in mice [4]
  • July 2026: FDA advisory committee votes 8–6, with one abstention, on TB-500 [8, 9]

Regulatory status as of October 2026

Neither TB-500 nor thymosin beta-4 is approved as a drug in the United States or elsewhere. In April 2026 the FDA removed TB-500 from its Category 2 list of bulk substances that raise significant safety concerns for compounding [10].

On 23–24 July 2026 the FDA Pharmacy Compounding Advisory Committee (PCAC) voted 8–6, with one abstention, to recommend allowing pharmacy compounding of TB-500 for the nominated use under review, contrary to FDA staff’s recommendation [5, 8, 11]. The vote is advisory, and any list change requires rulemaking [8]. As of 22 Oct 2026 the FDA had made no final decision. On 14 Oct 2026 an FDA interim access policy for compounding certain peptides went to the White House for review [12].

The 2026 WADA Prohibited List names “thymosin-β4 and its derivatives e.g. TB-500” under section S2 [13].

Available from Kalibra Labs

Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.

Look up a Certificate of Analysis by lot number →

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a natural 43-amino-acid protein, while TB-500 is a synthetic seven-amino-acid fragment (Ac-LKKTETQ) of it. The FDA states they are not the same substance [5].

Who discovered thymosin beta-4?

Allan L. Goldstein, then at George Washington University, discovered thymosin beta-4; his laboratory published its full sequence in 1981 [1, 3].

Is TB-500 FDA approved?

No. As of 22 Oct 2026 TB-500 is not FDA-approved. An FDA advisory committee voted on its compounding status in July 2026, but no final decision has been issued [8, 11].

Has TB-500 been studied in humans?

The FDA’s 2026 review found no published articles in which TB-500 was administered to people. Human clinical studies have used the full thymosin beta-4 protein [5].

Sources

  1. RegeneRx Biopharmaceuticals. Proxy statement (DEF 14A), director biography of Allan L. Goldstein. SEC, filed 10 Aug 2015. Link
  2. RegeneRx Biopharmaceuticals. Annual report (Form 10-K) for fiscal 2022. SEC, filed 11 Apr 2023. Link
  3. Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proc Natl Acad Sci U S A. 1981. PMID 6940133. Link
  4. Philp D, Badamchian M, Scheremeta B, Nguyen M, Goldstein AL, Kleinman HK. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic and aged mice. Wound Repair Regen. 2003. PMID 12581423. Link
  5. U.S. FDA. Briefing document: TB-500 (free base) and TB-500 acetate, Pharmacy Compounding Advisory Committee, 23–24 Jul 2026 (dated 15 May 2026). Link
  6. Safer D, Elzinga M, Nachmias VT. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991. PMID 1999398. Link
  7. RegeneRx Biopharmaceuticals. Letter to stockholders (SEER-2 update from HLB Therapeutics), 1 Sep 2026. Link
  8. McDermott Will & Schulte. Bulk list bound: PCAC backs majority of peptides in two-day public meeting. 27 Jul 2026. Link
  9. Moeller M. FDA Advisory Committee recommends adding six of seven peptides to compounding list. American Med Spa Association, 24 Jul 2026. Link
  10. Faviero GF, Asebey EJ (Frier Levitt). FDA to remove 12 popular peptides from the Category 2 “do not compound” list. 16 Apr 2026. Link
  11. Buchanan Ingersoll & Rooney. FDA advisory committee voted yes on six peptides. Now what? 18 Aug 2026. Link
  12. Office of Information and Regulatory Affairs (reginfo.gov). HHS/FDA, Interim Access Policy for Compounding Using Certain Peptides, RIN 0910-ZD94: received 14 Oct 2026, pending review. Link
  13. World Anti-Doping Agency. 2026 Prohibited List (S2 names thymosin-β4 and derivatives e.g. TB-500). Link

Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.

For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top